Diana Abdueva, PhD: Novel Blood-Based Assay Differentiates Seropositive and Seronegative Rheumatoid Arthritis, Healthy Subjects

News
Video

Diana Abdueva, PhD, states selecting the right therapy for rheumatoid arthritis is a complex challenge due to both the economic burden of therapies and the trial-and-error process patients often undergo.

In an interview with HCPLive, Diana Abdueva, PhD, CEO and founder of Aqtual, discussed her study “A Novel Blood-Based Assay Differentiates Seropositive and Seronegative Rheumatoid Arthritis from Healthy Individuals and Those with Other Inflammatory Diseases or Osteoarthritis,” presented at the American College of Rheumatology’s 2023 Convergence in San Diego, California.1

According to Abdueva, selecting the right therapy for rheumatoid arthritis (RA) is a complex challenge, posing difficulties for patients, clinicians, and payers due to both the economic burden of therapies and the trial-and-error process patients often undergo.

On average, a patient with RA changes therapy every 8 months, highlighting the lack of biomarkers predicting the patient's response to a specific therapy. Aqtual is pioneering the development of the first test for RA therapy selection across multiple drug classes. The recent American College of Rheumatology (ACR) presentation represents a significant milestone, revealing a platform capable of accessing tissue-specific signals from the synovium through a simple blood draw.

This technology mirrors advancements in oncology, where blood-based therapy guidance has reduced the need for invasive biopsies. While this marks the first step, ongoing clinical trials aim to predict therapy response across different drug classes, with a long-term vision of launching a test capable of predicting responses for patients with RA across various drug classes by Q1 2025.

Beyond RA, the company envisions expanding into other autoimmune conditions, such as inflammatory bowel disease (IBD) and lupus, showcasing a broader impact on chronic diseases. Emphasizing the company's commitment to patient-reported outcomes (PRO), efforts are underway to integrate PRO considerations into the development cycle, recognizing their importance in enhancing the understanding and impact of the test. As the company progresses, strong research and PRO integration will be prioritized over the next 12 months.

References

  1. Taylor P, Antonova J, Geis J, Dilger K, et al. A Novel Blood-Based Assay Differentiates Seropositive and Seronegative Rheumatoid Arthritis from Healthy Individuals and Those with Other Inflammatory Diseases or Osteoarthritis. Presented at: American College of Rheumatology Convergence 2023. San Diego, CA. November 10-15, 2023.
Related Videos
Discussing Post-Hoc Data on Ruxolitinib for Nonsegmental Vitiligo, with David Rosmarin, MD
1 KOL is featured in this series.
1 KOL is featured in this series.
Brendon Neuen, MBBS, PhD | Credit: X.com
4 KOLs are featured in this series
4 KOLs are featured in this series
M. Safwan Badr, MD: Novel Treatments for Central Sleep Apnea in Last 10 Years
Video 4 - Featuring 3 KOLs in, "Implementing Treat to Target in the Long-term in Inflammatory Bowel Disease "
Video 3 - Featuring 3 KOLs in, "How important is transmural healing as a treatment target in UC and CD?   Where does intestinal ultrasound fit in CD management?  "
© 2024 MJH Life Sciences

All rights reserved.